Inactive Instrument

Analyst Reco. Theseus Pharmaceuticals, Inc.

Equities

Stifel Lowers Price Target on Theseus Pharmaceuticals to $4 From $24, Maintains Buy Rating	23-07-14	MT
SVB Securities Adjusts Price Target on Theseus Pharmaceuticals to $10 From $18, Maintains Outperform Rating	23-07-14	MT
Needham Downgrades Theseus Pharmaceuticals to Hold From Buy	23-07-14	MT
Jefferies Downgrades Theseus Pharmaceuticals to Hold From Buy, Lowers Price Target to $3.50 From $22	23-07-14	MT
Cantor Fitzgerald Adjusts Price Target on Theseus Pharmaceuticals to $7 From $23, Maintains Overweight Rating	23-07-14	MT
HC Wainwright Adjusts Theseus Pharmaceuticals Price Target to $9 From $22, Maintains Buy Rating	23-07-14	MT
Wedbush Cuts Price Target on Theseus Pharmaceuticals to $7 From $24 on Termination of THE-630 in Gastrointestinal Stromal Tumors; Outperform Kept	23-07-14	MT
Stifel Starts Theseus Pharmaceuticals at Buy With $24 Price Target	23-03-16	MT
Needham Initiates Coverage on Theseus Pharmaceuticals With Buy Rating, $22 Price Target	22-12-14	MT
HC Wainwright Initiates Coverage on Theseus Pharmaceuticals With Buy Rating, $22 Price Target	22-06-30	MT
Jefferies Initiates Theseus Pharmaceuticals With Buy Rating, $23 Price Target	21-11-01	MT
SVB Leerink Starts Theseus Pharmaceuticals at Outperform With $28 Price Target	21-11-01	MT
Wedbush Starts Theseus Pharmaceuticals at Outperform With $24 Price Target	21-11-01	MT
Cantor Fitzgerald Starts Theseus Pharmaceuticals at Overweight With $25 Price Target	21-11-01	MT
Jefferies Starts Theseus Pharmaceuticals at Buy With $23 Price Target	21-11-01	MT

No results for this search